Insider Purchases: Inside the Buy
Tag: GLP-1
Medifast (MED) Stock Analysis: Can a Company Trading Below Its Cash Reinvent Itself?
Medifast (NYSE: MED) has nearly $170 million in cash, no debt, insider buying and a bold strategic pivot through Trilivy. But shrinking revenues and GLP-1 competition still cast a long shadow. Here's the complete bull vs. bear case.
💊 Pfizer (PFE): Why a Former Vanguard CEO Just Bought Nearly $1 Million of This 6.4% Dividend Stock
Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.